RU58841 is discussed as a potential hair loss treatment, with questions about its availability on Amazon and daily application dosage. Minoxidil and finasteride are also mentioned as treatments.
The conversation is about users trying to regain access to a Discord server related to pp405 research, with differing opinions on the effectiveness of pp405 for hair loss. Specific treatments like Minoxidil, finasteride, and RU58841 are not mentioned in the conversation.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
RU58841 powder is mixed with a 70% ethanol and 30% propylene glycol solution, with some users seeking PG-free alternatives. Minoxidil is also mentioned as a treatment option.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
RU58841 mixed with Minoxidil seems less effective over time, so the user plans to switch to a PG and Ethanol dilution for better results. They also consider using rosemary oil with Minoxidil to enhance RU58841 absorption.
The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.
Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
Hair cloning and injection of dermal papilla cells are discussed, with skepticism about their availability by 2023. Users mention Minoxidil, finasteride, and hair transplants as current treatments.
Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.
RU-58841 does not dissolve well in common Minoxidil solutions due to water content, requiring a 70/30 ethanol/propylene glycol mix. Users report using separate solutions for RU-58841 and finasteride/Minoxidil for better results.
Microneedling combined with tretinoin is discussed for its effectiveness in treating hair loss. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments.
People have reported hair thickening with Pyrilutamide, particularly using a 1% concentration. Some users are curious about the availability of different concentrations like 0.9%.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.
A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.
An individual's journey to treat their severe hair loss condition using the medications Pyrilutamide and RU58841. They will provide regular updates on their progress.
A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.